阿斯利康25亿美元落子京城,跨国药企的中国战略透露哪些信号?

药渡
26 Mar

来源:药渡撰文:Pharmadeep编辑:活力哈哈全球第六大研发中心落子北京阿斯利康的“中国棋局”再升级近日,阿斯利康宣布未来五年计划投资25亿美元,在北京建立全球第六大战略研发中心,这是其继上海之后在中国的第二个全球战略研发中心。新中心选址北京国际医药创新公园(BioPark),依托北京在生物学、人工智能和数据科学领域的优势,聚焦药物早期研究与临床开发。这一布局标志着阿斯利康对中国市场的战略投入...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10